Consensus Ligand Pharmaceuticals Incorporated

Stocks

LGND

US53220K5048

Pharmaceuticals

Real-time Estimate Cboe BZX 17:44:38 20/10/2026 +03			5-day change	1st Jan Change
311.58 ^USD	+4.81%		+1.05%	+62.22%

10-19	BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says	MT
10-19	BofA Securities Adjusts Price Target on Ligand Pharmaceuticals to $406 From $388, Maintains Buy Rating	MT

Evolution of the Average Target: Ligand Pharmaceuticals Incorporated

Evolution of the Target Price: Ligand Pharmaceuticals Incorporated

Changes in Analyst Recommendations: Ligand Pharmaceuticals Incorporated

679585546f8779506ea12b1d.lyQynmzKYng2jrrsIvcGy0cPkuWcJEy7Nv52mn4LVa4.0hQf2D6NEwJC1MDeSZZJjSlWwoPlTjnwApsv2DtTEd-jUGPxOK8IAVX-7w~c305f586159f2ebd9a5ab811a8b3901a

Analysts' recommendations: Ligand Pharmaceuticals Incorporated

10-19	BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says	MT
10-19	BofA Securities Adjusts Price Target on Ligand Pharmaceuticals to $406 From $388, Maintains Buy Rating	MT
09-25	Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target	MT
08-07	RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating	MT
08-03	Oppenheimer Adjusts Ligand Pharmaceuticals PT to $326 From $285, Maintains Outperform Rating	MT
07-15	RBC Capital Adjusts Price Target on Ligand Pharmaceuticals to $340 From $262, Maintains Outperform Rating	MT
05-28	BofA Securities Adjusts Ligand Pharmaceuticals Price Target to $266 From $263	MT
05-08	RBC Raises Price Target on Ligand Pharmaceuticals to $262 From $252, Keeps Outperform Rating	MT
04-28	RBC Raises Price Target on Ligand Pharmaceuticals to $252 From $235, Keeps Outperform Rating	MT
03-30	RBC Raises Price Target on Ligand Pharmaceuticals to $64 From $48, Keeps Outperform Rating	MT
03-11	BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target	MT
02-27	Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating	MT
12-10	RBC Lifts Price Target on Ligand Pharmaceuticals to $235 From $234, Keeps Outperform Rating	MT
12-09	Citigroup Initiates Ligand Pharmaceuticals at Buy With $270 Price Target	MT
11-25	Ligand Pharmaceuticals Expected to Issue Conservative 2026 Outlook at Upcoming Investor Day, RBC Says	MT
11-10	RBC Raises Price Target on Ligand Pharmaceuticals to $234 From $185, Keeps Outperform Rating	MT
11-03	Oppenheimer Raises Price Target on Ligand Pharmaceuticals to $250 From $190, Keeps Outperform Rating	MT
03/09/25	Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $190 From $167, Maintains Outperform Rating	MT
09/05/25	Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $145 From $142, Maintains Outperform Rating	MT
10/04/25	Stifel Initiates Ligand Pharmaceuticals at Buy With $143 Price Target	MT
28/02/25	Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $142 From $151, Maintains Outperform Rating	MT
28/02/25	RBC Raises Price Target on Ligand Pharmaceuticals to $155 From $143, Keeps Outperform Rating	MT
11/12/24	Oppenheimer Adjusts Ligand Pharmaceuticals Price Target to $151 From $135, Maintains Outperform Rating	MT
11/12/24	RBC Raises Price Target on Ligand Pharmaceuticals to $143 From $141, Keeps Outperform Rating	MT
03/12/24	RBC Lifts Price Target on Ligand Pharmaceuticals to $141 From $140, Keeps Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LIGAND PHARMACEUTICALS INCORPORATED					+16.3%
	ELI LILLY AND COMPANY					+7.22%
	JOHNSON & JOHNSON					+10.09%
	ABBVIE INC.					-0.03%
	ROCHE HOLDING AG					+1.02%
	MERCK & CO., INC.					+10.39%
	NOVARTIS AG					-0.24%
	ASTRAZENECA PLC					+27.41%
	AMGEN INC.					-7.05%
	GILEAD SCIENCES, INC.					+4.63%
	Average					+6.98%
	Weighted average by Cap.					+6.28%